XML 25 R14.htm IDEA: XBRL DOCUMENT
v3.23.2

SHARE OPTION PLANS AND ESPP | 6 Months Ended
--- | ---
Jun. 30, 2023
Share-Based Payment Arrangement, Recognized Amount [Abstract] |
Share option plans and ESPP | SHARE OPTION PLANS AND ESPP In September 2015, the Company adopted the 2015 Omnibus Incentive Plan (the “2015 Plan”). Under the 2015 Plan, the Company can issue various types of equity compensation awards such as share options, restricted shares, performance shares, restricted share units (“RSUs”), performance-based share units (“PSUs”), long-term cash awards and other share-based awards. Options granted under the 2015 Plan generally have a two-year or four-year vesting period and expire ten years after the date of grant. Options granted under the 2015 Plan that are canceled or forfeited before expiration become available for future grants. RSUs granted under the 2015 Plan generally vest over a three year period. PSUs granted under the 2015 Plan generally vest between a three- and six-year period as performance targets are attained. RSUs and PSUs granted under the 2015 Plan that are canceled before expiration become available for future grants. As of June 30, 2023, 18,945,024 ordinary shares were available for grant under the 2015 Plan. A summary of the status of the Company’s option plans as of June 30, 2023 and changes during the period then ended is presented below:
| Six months ended June 30, 2023
| Unaudited
| Number of options |  | Weighted average exercise price
Outstanding at beginning of year | 8,786,364 |  |  | $ | 37.27 |
Granted | 779,388 |  |  | 74.07 |
Exercised | (704,027) |  |  | 13.93 |
Forfeited and canceled | (239,866) |  |  | 75.47 |
Outstanding as of June 30, 2023 | 8,621,859 |  |  | $ | 41.44 |
Exercisable options | 6,862,376 |  |  | $ | 30.57 |
For the six months ended June 30, 2023, options to purchase 704,027 ordinary shares were exercised, resulting in the issuance of 704,027 ordinary shares. A summary of the status of the Company’s RSUs and PSUs as of June 30, 2023 and changes during the period then ended is presented below.
| Six months ended June 30, 2023
| Unaudited
| Number of RSU/PSUs |  | Weighted average grant date fair value
Unvested at beginning of year | 5,377,459 |  |  | $ | 66.87 |
Granted | 1,267,758 |  |  | 76.04 |
Vested | (770,163) |  |  | 84.96 |
Forfeited and cancelled | (121,741) |  |  | 92.59 |
Unvested as of June 30, 2023 (1) | 5,753,313 |  |  | 65.95 |
(1) Includes PSUs that have a mix of service, market and other milestone performance vesting conditions which are vested upon achievements of performance milestones that are not probable as of June 30, 2023, in accordance with ASC 718 "Compensation — Stock Compensation" as follows:
| June 30, 2023
| Number of PSUs |  | Fair value at grant date per PSU |  | Total fair value at grant date
| 2,703,852 |  |  | $ | 48.16 |  |  | $ | 130,218 |
| 189,029 |  |  | 76.97 |  |  | 14,550 |
| 124,701 |  |  | 80.59 |  |  | 10,050 |
| 7,605 |  |  | 87.66 |  |  | 667 |
| 10,532 |  |  | 94.94 |  |  | 1,000 |
| 161,912 |  |  | 114.26 |  |  | 18,500 |
| 3,197,631 |  |  |  |  | $ | 174,985 |
These PSUs will be expensed over the performance period when the vesting conditions become probable in accordance with ASC 718. In September 2015, the Company adopted an employee share purchase plan (“ESPP”) to encourage and enable eligible employees to acquire ownership of the Company’s ordinary shares purchased through accumulated payroll deductions on an after-tax basis. In the United States, the ESPP is intended to be an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code and the provisions of the ESPP are construed in a manner consistent with the requirements of such section. As of June 30, 2023, 4,787,003 ordinary shares were available to be purchased by eligible employees under the ESPP. The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants. For market condition awards, the Company also applied the Monte-Carlo simulation model. The Company assessed fair value using the following underlying assumptions:
| Six months ended June 30, |  | Year ended December 31, 2022
| 2023 |  | 2022 |
| Unaudited |  | Audited
Stock Option Plans |  |  |  |  |
Expected term (years) | 5.50-6.00 |  | 5.33-5.83 |  | 5.33-5.83
Expected volatility | 63%-67% |  | 60%-62% |  | 60%-62%
Risk-free interest rate | 3.48%-4.10% |  | 1.58%-3.04% |  | 1.58%-4.23%
Dividend yield | 0.00 | % |  | 0.00 | % |  | 0.00 | %
ESPP |  |  |  |  |
Expected term (years) | 0.50 |  | 0.50 |  | 0.50
Expected volatility | 56 | % |  | 51 | % |  | 51%-77%
Risk-free interest rate | 4.76 | % |  | 0.19 | % |  | 0.19%-2.52%
Dividend yield | 0.00 | % |  | 0.00 | % |  | 0.00 | %
The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three and six months ended June 30, 2023 and 2022, and the year ended December 31, 2022 was:
| Three months ended June 30, |  | Six months ended June 30, |  | Year ended December 31, 2022
| 2023 |  | 2022 |  | 2023 |  | 2022 |
| Unaudited |  | Unaudited |  | Audited
Cost of revenues | $ | 2,023 |  |  | $ | 1,029 |  |  | $ | 4,029 |  |  | $ | 1,981 |  |  | $ | 4,690 |
Research, development and clinical studies | 8,537 |  |  | 7,624 |  |  | 20,316 |  |  | 14,425 |  |  | 30,790 |
Sales and marketing | 10,213 |  |  | 6,802 |  |  | 21,857 |  |  | 13,457 |  |  | 28,826 |
General and administrative | 11,967 |  |  | 10,368 |  |  | 25,622 |  |  | 21,005 |  |  | 42,649 |
Total share-based compensation expense | $ | 32,740 |  |  | $ | 25,823 |  |  | $ | 71,824 |  |  | $ | 50,868 |  |  | $ | 106,955 |

X
- References No definition available. + Details
Name: | us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//505/tableOfContent Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContent + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration